x Health Men's Health Children's Health Nutrition and Wellness Reproductive Health Health & Science Digital News Videos Opinions Cartoons Education E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise BULK SMS E-Learning Digger Classified The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
Login ×
BTV
VAS
DCX
RMS

Gilead shares rise after United States approves remdesivir as COVID-19 drug

Health & Science - By Reuters | October 23rd 2020 at 07:57:20 GMT +0300
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S. [Reuters]

Shares of Gilead Sciences Inc rose 6% on Friday after its antiviral drug, remdesivir, became the first and only approved treatment for COVID-19 in the United States.

The U.S. health regulator’s approval on Thursday for its use in hospitalized patients came despite the World Health Organization last week saying the drug did not have a substantial effect on patients’ length of hospital stay or chances of survival in a global trial.

The U.S. Food and Drug Administration’s (FDA) backing signals its confidence in Gilead’s U.S.-based study results, which showed the drug was able to cut time to recovery in patients, Piper Sandler analyst Tyler Van Buren said in a client note.

Remdesivir has been available under an FDA emergency use authorization since May, after a study led by the National Institutes of Health showed it reduced hospital stays by five days.

The drug, given intravenously, could generate over $1 billion in sales during the second half of the year at the current case rate, analyst Van Buren said.

Covid 19 Time Series

 

Remdesivir, which will be sold under the brand name Veklury, costs $3,120 for a five-day treatment course, or $2,340 for government purchasers such as the Department of Veterans Affairs.

Shares of Gilead were up 5.67% at $64.11 before the bell.


Gilead Sciences Inc COVID-19

Top Stories

Covid-19: 138 test positive as three others die
Health & Science - By Mercy Asamba


How alcoholism trickles down generations
Health & Science - By Nancy Nzalambi


Do you need to deworm? These are the signs to look out for
Health & Science - By Jael Mboga


KUCO: The strike is still on
Health & Science - By Judah Ben-Hur


Is vitiligo curable?
Health & Science - By Graham Kajilwa


Does beer make you fat?
Health & Science - By By Bob Otieno


KNH yet to lower cost of testing for virus to Sh1,000
Health & Science - By Anyango Otieno


Latest Stories

Woman's cry for justice after losing uterus in wrong surgery
Health & Science - By Mactilda Mbenywe


Covid-19: Kenya records 166 new cases, three deaths
Health & Science - By Vincent Kejitan


KUCO: The strike is still on
Health & Science - By Judah Ben-Hur


Covid-19: 138 test positive as three others die
Health & Science - By Mercy Asamba


Covid-19: 123 positives, 412 recoveries
Health & Science - By Betty Njeru


Nurses vow to continue strike until MoU signed
Health & Science - By Judah Ben-Hur


Covid-19: Positive cases under the 100-mark three days in a row
Health & Science - By Judah Ben-Hur


Pfizer appoints Patrick van der Loo as Regional President for Africa and the Middle East
Health & Science - By Standard Reporter


Medics stay put as county decries lack of cash
Health & Science - By Benard Sanga


When swallowing or passing stool needs painkillers
Health & Science - By Yvonne Kawira


//

Stay Ahead!

Access premium content only available
to our subscribers.

Or Login With Your Standard Account
Support independent journalism
×
Create An Account
Support independent journalism
I have an account Log in
Reset Password
Support independent journalism
Log in